Zhitong Financial APP learned that this week, under the influence of the Zantac lawsuit,$GlaxoSmithKline PLC (GSK.US) $、$Sanofi SA (SNY.US) $、$Haleon (HLN.US) $And$Pfizer Inc (PFE.US) $In total, the market capitalization lost more than $44 billion, which attracted the attention of JPMorgan Chase & Co. Bank analysts Richard Vosser and James Gordon believe that the market capitalization of these companies has been hit "more than the worst-case scenario" this week, and they believe that the market has not fairly considered any potential liability of Zantac among the relevant companies.

The bank said GlaxoSmithKline PLC may have the clearest evidence that its use of Zantac is related to individual patients because the company has been selling the product by prescription since 1983, but they still see the $12 billion shock to the company's market capitalization this week as a "potential overreaction". However, Vosser and Gordon said they did not see a change in the problems facing GlaxoSmithKline PLC until the first case opened in February.

On the contrary, they believe that Sanofi may not be liable for any litigation damages, given that the compensation agreement between Sanofi and Boehringer Ingelheim is currently under arbitration. Analysts say that even if Sanofi is not exempt from all legal liability, their exposure to sales of prescription drugs is likely to be lower than that of GlaxoSmithKline PLC, and that the company's market capitalization loss of $16.5 billion this week could mean that "the stock has now digested overly pessimistic expectations for Zantac". The bank rated Sanofi as "overweight" and GlaxoSmithKline PLC as "neutral".